Select Biosciences Ltd

Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech

Date Posted: Wednesday, October 24, 2007

Print Email to a friend

Argenta Discovery Ltd. has announced that it has extended its integrated contract drug discovery agreement with Genentech, Inc. for a further two-year period.

The first collaboration project under the agreement was announced in December 2005, and a second project was entered into in March 2007. The two programmes utilize Argenta's expertise in computer-aided drug design (CADD), medicinal chemistry, and in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech.

Commenting on the extended agreements, Dr. Christopher Ashton, Argenta’s Chief Executive Officer, said, “We are delighted that Genentech has chosen to extend the collaboration for another two years. The two projects have made excellent progress and a good working relationship has been established between both teams of scientists over the past two years.

We believe this extension illustrates Argenta’s key strengths and continued commitment to deliver high quality, time- and cost-effective integrated drug discovery services and expertise. We very much look forward to continuing and growing our successful collaboration with Genentech.”

Financial terms of the deal, which incorporates a number of funded FTEs at Argenta for the next two years, were not disclosed. The agreement provides further options to expand the relationship.

Further Information:

Related news from our archive

Argenta Announces a Significant Collaboration Milestone in the Development of Improved Bronchodilators for COPD
Argenta in a joint programme with AstraZeneca has nominated the first candidate drug to enter formal development by AZ, triggering a milestone payment to Argenta.

Argenta Discovery Announces Contract Drug Discovery Collaboration with CellCentric
The collaboration aims to discover inhibitors for two potential epigenetic-related therapeutic targets.

Argenta Discovery Announces Contract Drug Discovery Collaboration with BioTie Therapies
Scientists from the two companies will exploit Argenta’s expertise in medicinal chemistry, computer-aided drug design and early ADME to advance one of BioTie’s therapeutics programmes.

Argenta Discovery Announces Second Two-Year Drug Discovery Collaboration with Genentech
Argenta to use its expertise in computer-aided drug design, medicinal chemistry and biology to discover new chemical entities acting against a second drug target defined by Genentech.